TARRYTOWN, N.Y.--(BUSINESS WIRE)--TechnoVax, Inc., a biotechnology developer of novel vaccines, has received a one-year $509,623 SBIR grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The grant is to support TechnoVax program for the development of an RSV vaccine utilizing its proprietary VLP technology.
RSV is a major respiratory infectious disease in infants, children, and adults. Persons with high-risk conditions including the elderly and adults with underlying chronic cardiac or pulmonary disease can experience extremely severe re-infections. In the USA only, RSV is responsible for about 100,000 infant and 175,000 elderly hospitalizations due to RSV related secondary infections (pneumonia and bronchitis) leading to the death of 14,000 elderly patients. At present there is no approved vaccine to protect against RSV on the market!
“We greatly appreciate this NIAID grant that will accelerate the development of this much needed vaccine,” stated Dr. Jose Galarza, CEO of TechnoVax. “This award recognizes not only the innovative research carried out at TechnoVax but also emphasizes the importance of developing such RSV vaccine.”
About VLPs and TechnoVax’ Vaccine Program
Technovax’ VLP technology is a novel way to produce vaccines against dangerous viruses as VLPs contain no infectious material and are highly immunogenic. TechnoVax' VLP vaccine technology uses a rapid, safer and more effective cell-based system for development and production, reducing the time and costs of more traditional vaccine production systems. The VLP vaccine technology is one of the most advanced technologies in the vaccine field. TechnoVax is presently evaluating in preclinical phase vaccines to protect against influenza, respiratory syncytial virus and dengue.
About TechnoVax Inc.
TechnoVax is a privately held biotechnology company based in Westchester County (New York) and specializes in vaccine development using its unique and innovative VLP platform technology. The company is committed to develop safe and highly effective novel vaccines to address significant unmet medical needs of global impact.
For more information, visit: www.technovax.com